Atopic Dermatitis Landscape

Dupixent is now the world’s third biggest selling medicine, and much of its revenue comes from atopic dermatitis. The field is increasingly crowded, with AbbVie’s Rinvoq one of several challengers pushing to raise the bar:

August 29, 2024

How Much Do Large BioPharma Companies Spend on Capex?

Capital expenditures are usually overlooked in the biopharma world, because the industry is relatively capital-light. However, the race to produce GLP-1s and the increasing complexity of new types of medicines are changing this perspective.

August 29, 2024

Top 15 Immunology Medicines by Q2 2024 Sales

Immunology ranks as the second-largest segment in the biopharmaceutical industry by sales, following oncology. This analysis delves into the 15 top-selling immunology medicines in Q2, highlighting the key growth drivers behind their performance:

August 29, 2024

Top 10 BioPharma Companies by Revenue Q2 2024

Several biopharmaceutical companies have reported an increase in revenue and earnings guidance with their second-quarter earnings. This article takes a closer look at the ten largest companies by revenue and explores the factors behind their financial results.

August 29, 2024

Top 15 Oncology Medicines by Q2 2024 Sales

Oncology remains the largest segment of the BioPharma industry, hosting many of the industry’s top-selling medicines. Several key drugs are facing LOEs soon. Here’s a closer look behind key catalysts driving development and growth:

August 29, 2024

Roche: 10 Year Sales Evolution

Roche has achieved steady growth in the last several years, yet underneath, it has undergone significant change. Here are a few highlights about how it has evolved over the last decade:

August 21, 2024

Top 10 Medicines by Q2 2024 Sales

All major public BioPharma companies have reported Q2 results. Here's a look behind the world's 10 top-selling medicines:

August 21, 2024

IRA's First 10: How Much Revenue is at Stake?

In the initial 10 medicines under the IRA, there is a huge variance in terms of how much each company's revenue is dependent on that medicine. Here's a fresh take on the relative impact:

August 21, 2024

Alzheimer's Disease Landscape

Last month, the EMA rejected Biogen's Leqembi, despite the FDA’s previous approval, citing major safety risks that involve ARIA (brain bleeding and/or swelling). Here’s a closer look at Leqembi and other promising Alzheimer’s treatments:

August 15, 2024

Lilly and Novo: How do GLP-1 Sales Compare? (Q2 '24)

Last week, both Eli Lilly and Company and Novo Nordisk reported quarterly results, where the focus continued to be on the companies' GLP-1 medicines. Here are some notable updates on manufacturing expansion, intl. sales, and access.

August 14, 2024